Septerna, Inc. Board of Directors

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.

Dr. Jeffrey T. Finer M.D., Ph.D.

Dr. Jeffrey T. Finer M.D., Ph.D.

Co-Founder, CEO, President & Director

Dr. Daniel Long DPHIL

Dr. Daniel Long DPHIL

Senior Vice President of Drug Discovery

Ms. Ran Xiao C.F.A., M.B.A.

Ms. Ran Xiao C.F.A., M.B.A.

Interim CFO and VP of Finance & Business Operations

Dr. Robert J. Lefkowitz M.D.

Dr. Robert J. Lefkowitz M.D.

Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board

Dr. Patrick Sexton Ph.D.

Dr. Patrick Sexton Ph.D.

Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board

Dr. Arthur Christopoulos BPHARM, Ph.D.

Dr. Arthur Christopoulos BPHARM, Ph.D.

Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board

Mr. Richard Hansen Ph.D.

Mr. Richard Hansen Ph.D.

Vice President of Technology

Ms. Samira Shaikhly

Ms. Samira Shaikhly

Chief People Officer

Mr. Uwe Klein Ph.D.

Mr. Uwe Klein Ph.D.

Senior Vice President of Biological Sciences

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.